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Abstract
Rationale—Varenicline, a smoking-cessation agent, may be useful in treating alcohol use 
disorders. An important consideration when studying factors that influence drinking/relapse is 
influence of the pharmacological effects of alcohol on these behaviors. Pre-exposure to alcohol 
(priming) can increase craving, drinking and seeking behaviors.
Objectives—The primary goal of this work was to determine the effects of varenicline on 
alcohol-primed self-administration and seeking behavior in male Long Evans rats.
Methods—First, we assessed whether varenicline (0, 0.3, 1, 3 mg/kg, IP) has alcohol-like 
discriminative stimulus effects and whether varenicline alters sensitivity to alcohol in rats trained 
to discriminate a moderate alcohol dose (1 g/kg, IG) vs. water. Second, animals trained to self-
administer alcohol underwent assessments to test the effects of: (i) varenicline (0, 0.3, 1, 3 mg/kg, 
IP) on self-administration, (ii) alcohol priming (0, 0.3, 1 g/kg, IG) on self-administration and 
seeking behavior, (iii) varenicline (1 mg/kg) in combination with alcohol priming (1 g/kg) on 
these behaviors.
Results—Varenicline did not substitute for alcohol, but disrupted the expression of sensitivity to 
alcohol. Varenicline decreased self-administration, but only at a motor impairing dose (3 mg/kg). 
Alcohol priming decreased self-administration and seeking behavior. Varenicline (1 mg/kg) 
blocked this effect under self-administration conditions, but not seeking conditions, which 
effectively resulted in increased alcohol intake.
Conclusions—These findings suggest the importance of further behavioral and mechanistic 
studies to evaluate the use of varenicline in treating alcohol use disorders and its potential impact 
on drinking patterns in smokers using varenicline as a smoking cessation aid.
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Introduction
Alcohol use disorders are a continuing world-wide public health issue. For this reason there 
is great interest in better understanding behaviors that lead to excessive drinking and 
developing effective treatments for reducing ongoing drinking and preventing relapse. To 
date, the US Food and Drug Administration (FDA)-approved treatments for alcohol 
dependence are naltrexone (opioid antagonist), disulfiram (aldehyde dehydrogenase 
inhibitor), and acamprosate (actions on GABA and glutamate). These compounds have 
different mechanisms of action and each have demonstrated efficacy in a limited subset of 
the patient population (Liang and Olsen 2014). However, there is continued emphasis on 
developing novel therapeutics and investigating potential novel pharmacological targets for 
the treatment of alcohol use disorders (AUDs).
One target that has been receiving increased attention is the nicotinic acetylcholine system. 
This is of particular interest given that clinical studies show high comorbidity between 
smoking and heavy drinking (~80% of heavy drinkers also smoke) and that heavy drinking 
may influence nicotine dependence (Chatterjee and Bartlett 2010; Dani and Harris 2005; 
Falk et al. 2006; Grant 1998; McKee et al. 2007). For this reason, there has been growing 
interest in the pharmacological compound varenicline for the treatment of AUDs. 
Varenicline is currently FDA-approved for use as a smoking cessation agent (Cahill et al. 
2012), and is a partial nicotinic acetylcholine receptors (nAChRs) agonist at α4β2, α3β2 and 
α6 and a full agonist at α3β4 and α7 nAChRs (Coe et al. 2005; Rollema et al. 2009). In 
clinical studies, varenicline has been shown to have efficacy in decreasing alcohol craving 
and consumption, particularly in smokers (Fucito et al. 2011; Mitchell et al. 2012). 
Additionally, evidence from human, nonhuman primates and rodent studies have shown that 
varenicline may also be useful in decreasing alcohol consumption and alcohol-seeking 
behaviors (Childs et al. 2012; Feduccia et al. 2014; Hendrickson et al. 2010; Kaminski and 
Weerts 2014; Litten et al. 2013; McKee et al. 2009; Mitchell et al. 2012; Steensland et al. 
2007; Wouda et al. 2011). Importantly, varenicline appears to selectively attenuate alcohol-
related behaviors as compared to naltrexone (Steensland et al. 2007).
An important consideration when studying factors that influence drinking and relapse is the 
influence of the pharmacological effects of alcohol on these behaviors, specifically the role 
of alcohol priming (e.g., alcohol pre-exposure leading to additional alcohol consumption or 
increased craving). Numerous clinical studies have demonstrated that alcohol priming not 
only increases craving in alcoholics (Hodgson et al. 1979; Ludwig and Wikler 1974), but 
also increases alcohol seeking behavior (Bigelow et al. 1977). Importantly, these effects are 
not limited to alcohol-dependent individuals. For example, non-dependent social drinkers 
report increased desire for alcohol following an alcohol priming dose (Kirk and de Wit 
2000). In addition, non-alcoholics tend to choose alcohol over other types of reinforcement 
and show increased alcohol consumption following an alcohol priming dose (Chutuape and 
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de Wit 1994; de Wit and Chutuape 1993; Hobbs et al. 2005). In preclinical animal models, 
an experimenter-administered priming dose of alcohol effectively reinstates alcohol-seeking 
behavior (Gass and Olive 2007; Le et al. 1999; Le et al. 1998; Vosler et al. 2001).
The effects of varenicline on alcohol-primed self-administration and alcohol seeking 
behavior have not been previously evaluated, which is important given the impact of 
priming cues on subsequent drug self-administration and seeking behavior. Therefore, the 
primary goal of this work was to determine the effects of varenicline on alcohol-primed 
behavior. Specifically, using operant self-administration methods, the effects of varenicline 
on maintenance of alcohol self-administration and alcohol-seeking behavior (under “probe-
extinction” conditions) following alcohol priming injections were assessed. Interestingly, it 
has been suggested that drug-related priming effects may be related to the discriminative 
stimulus/interoceptive effects of the drug (Colpaert 1987; Colpaert et al. 1979; DiChiara and 
Reinhart 1995; Gerber and Stretch 1975; Jackson et al. 2003; Stolerman 1992; Stretch and 
Gerber 1973). For example, in self-administration models, drugs with similar discriminative 
stimulus effects as the self-administered drug may also prime drug seeking behavior (Anker 
and Carroll 2010; DiChiara and Reinhart 1995; Fattore et al. 2003; Gerber and Stretch 
1975). Therefore, we first sought to determine whether varenicline has alcohol-like 
discriminative stimulus effects and whether varenicline pretreatment alters sensitivity to 
alcohol using standard drug discrimination methods. Rats were trained to discriminate a 
moderate alcohol dose (1 g/kg) from water. This alcohol training dose was used as it is 
comparable to alcohol intake achieved in the self-administration experiments. This 
assessment allows us to determine whether varenicline-induced changes in alcohol priming-
related behavior may be related to altered sensitivity to the alcohol priming cue. Within the 
context of the existing literature showing varenicline-induced decreases in alcohol drinking 
and self-administration (as discussed above), we hypothesized that varenicline would 
prevent alcohol priming-induced increases in self-administration and seeking.
Materials and Methods
Animals
34 Long-Evans rats singly housed in ventilated cages were used for these studies. For the 
discrimination studies in Experiment 1, rats (n=12) were maintained at 325–340 g. For all 
the self-administration experiments, rats weighed 350–400 grams at the beginning of testing 
and had food and water available ad libitum in the home cage. The following is the 
breakdown of the rats used in the self-administration experiments (Experiments 2 (n=12), 3 
(n=10), 4 (n=9), 5 (n=12) and 6 (n=9)). In an effort to reduce the number of rats required for 
this work, rats in Experiment 2 were also used in Experiment 5 and rats in Experiment 3 
were also used in Experiments 4 and 6 (one rat was not included in these latter experiments 
due to inconsistent baseline performance). The design of studies and animal use is shown in 
Figure 1. The colony room was maintained on a 12 hour light/dark schedule (lights on at 
07:00) with all experiments being conducted during the light portion of the schedule. 
Animals were under continuous care and monitoring by veterinary staff from the Division of 
Laboratory Animal Medicine (DLAM) at UNC-Chapel Hill. All procedures were carried out 
in accordance with the NIH Guide for Care and Use of Laboratory Animals and institutional 
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guidelines. All protocols were approved by the UNC Institutional Animal Care and Use 
Committee (IACUC). UNC-Chapel Hill is accredited by the Association for Assessment and 
Accreditation of Laboratory Animal Care (AAALAC).
Behavioral Training Procedures
Alcohol discrimination training – See Figure 1 for timeline—Rats were trained 
using the same behavioral chambers and procedures as previous studies from this laboratory 
(Besheer et al. 2012; Besheer et al. 2014; Besheer et al. 2009). Briefly, immediately 
following intragastric gavage (IG) administration of alcohol (1 g/kg) or water rats were 
placed in the chambers. Following a 10 minute delay, both response levers were extended 
into the chamber (beginning of the 15 minute session). On alcohol sessions (i.e., following 
alcohol administration (1 g/kg, IG)), completion of a fixed ratio 10 (FR10) schedule of 
reinforcement (e.g., every 10th response) on the alcohol-appropriate lever resulted in 
presentation of sucrose. Similarly, on water sessions (i.e., following IG water 
administration), completion of an FR10 on the water-appropriate lever resulted in sucrose 
delivery. During both alcohol and water sessions, responding on the inappropriate lever was 
recorded but had no programmed consequence. Testing began once the following criteria 
were met: the percentage of alcohol- and water-appropriate responses emitted prior to the 
first reinforcer and during the entire session was >80% for 8/10 consecutive days.
Testing—Test sessions were similar to training sessions except that they were 2 minutes in 
duration (following 10 min delay) and completion of an FR10 on either lever resulted in 
sucrose reinforcement, allowing for assessment of the effects of treatment on overall 
response rate. Test sessions were interspersed with standard training sessions.
Alcohol self-administration training – See Figure 1 for timeline—Rats were 
trained using the same behavioral chambers and procedures as previous studies from this 
laboratory (Besheer et al. 2013; Besheer et al. 2010; Cannady et al. 2013), with the addition 
of infrared photobeams (that divided the chamber into 4 parallel zones) to measure 
locomotor activity during sessions (number of beam breaks). Self-administration sessions 
(30 min) took place 5 days per week (M-F) with both response levers remaining on a fixed 
ratio 2 (FR2) schedule of reinforcement such that every second response on either lever 
resulted in delivery of a corresponding reinforcement (i.e., alcohol or water). A sucrose 
fading procedure was used in which alcohol was gradually added to the 10% (w/v) sucrose 
solution. The exact order of exposure was as follows: 10% sucrose (w/v)/2% (v/v) alcohol 
(10S/2A), 10S/5A, 10S/10A, 5S/10A, 5S/15A, 2S/15A. There were two sessions at each 
concentration. Following sucrose fading, sweetened alcohol (2S/15A) and water continued 
as reinforcers for the remainder of the study.
Experimental Procedures (see Figure 1)
Experiment 1: Effects of varenicline on the discriminative stimulus effects of 
alcohol—To assess whether varenicline has alcohol-like discriminative stimulus effects, 
rats received varenicline (0, 0.3, 1, 3 mg/kg, IP; n=6) 30 min prior to the start of the 
discrimination test session. To determine whether varenicline alters the discriminative 
stimulus effects of the alcohol training dose (1 g/kg), rats received varenicline (0, 0.3, 1, 3 
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mg/kg, IP; n=6) 20 min prior to alcohol (1 g/kg, IG; i.e., 30 min before the start of the 
discrimination test session). Within each assessment, doses were assigned in a repeated 
measures design with each rat receiving all treatments in a randomized order, with at least 
two baseline sessions between testing days.
Experiment 2: Effects of varenicline on maintenance of alcohol self-
administration—To assess the effects of varenicline pretreatment on the maintenance of 
alcohol self-administration, on test days, rats received varenicline (0, 0.3, 1, 3 mg/kg, IP) 30 
minutes prior to a self-administration session. Doses were assigned in a repeated measures 
design with each rat receiving all treatments in a randomized order, with at least two 
baseline sessions between testing days. At the conclusion of varenicline testing, the rats 
were tested to examine locomotor behavior independent of the self-administration procedure 
as described in Besheer et al. (2013). Rats received varenicline (0 or 3 mg/kg, IP) 30 min 
before placement in the locomotor activity chamber. Each rat experienced two 30-minute 
locomotor sessions in which the varenicline dose order was randomized. These locomotor 
assessments were interspersed with self-administration sessions with at least 3 days between 
tests. On the locomotor test days, self-administration sessions were withheld.
Experiment 3: Effects of alcohol priming on maintenance of alcohol self-
administration—To characterize the effects of alcohol priming on ongoing self-
administration, rats received alcohol (0.3, 1.0 g/kg, IG) or water (IG) 10 minutes prior to a 
self-administration session. Doses were administered in a repeated measures design with 
each rat receiving each treatment in a randomized order, with at least two baseline sessions 
between testing days.
Experiment 4: Effects of varenicline on alcohol self-administration following 
priming—To determine the effects of varenicline on alcohol-primed self-administration, 
rats received varenicline (0 or 1 mg/kg, IP) 20 minutes prior to the alcohol (0 or 1 g/kg, IG) 
injection and 10 minutes later underwent a self-administration session. Each rat received 
each treatment in a randomized order, with at least two baseline sessions between testing 
days.
Experiment 5: Effects of alcohol priming on alcohol-seeking behavior—In order 
to assess the impact of alcohol priming on the resilience of alcohol seeking behavior under 
different conditions, rats were tested under “probe-extinction” conditions. For these tests, all 
cues were activated following completion of each FR2 (i.e., cue light illuminated, pump 
sound activated), however no reinforcers were delivered (i.e., no alcohol or water). On test 
days, rats received the alcohol priming dose (0, 0.3, 1 g/kg, IG) 10 minutes prior to the 
session. Rats received each treatment in a randomized order, with at least two baseline 
sessions between tests.
Experiment 6: Effects of varenicline on alcohol-seeking behavior following 
priming—To determine the effects of varenicline on alcohol-primed seeking behavior, rats 
received varenicline (0 or 1 mg/kg, IP) 20 minutes prior to the alcohol (0 or 1 g/kg, IG) 
injection. 10 min later each rat underwent a “probe-extinction” session as described in 
Randall et al. Page 5













Experiment 5. Rats received each treatment in a randomized order, with at least two baseline 
sessions between testing days.
Drugs
Alcohol (95% w/v, Pharmaco-AAPER, Shelbyville, KY) and sucrose were diluted with 
distilled water for self-administration sessions. For the alcohol discrimination studies and for 
all priming injections in the self-administration studies, alcohol was diluted to 20% (v/v) 
with distilled water which also served as the water control. Varenicline tartrate (Abcam 
Pharmaceuticals, Cambridge, UK) was dissolved in 0.9% saline solution which also served 
as the vehicle control. Doses for Experiments 1 and 2 were selected based on previous 
studies (Ginsburg and Lamb 2013; LeSage et al. 2009; Panlilio et al. 2014). Doses for 
Experiments 4 and 6 were determined based on the outcome of Experiments 1 and 2. For 
priming and alcohol discrimination experiments, alcohol was administered via intragastric 
gavage (IG) with volume varied by rat weight to achieve desired dose. Varenicline was 
administered via intraperitoneal (IP) injection at a volume of 1 ml/kg.
Statistical Analyses
For the discrimination assessments (Experiment 1), alcohol-appropriate responses (prior to 
delivery of the first reinforcer) and response rates were analyzed with one-way repeated 
measures analysis of variance (RM ANOVA). For the self-administration experiments, 
alcohol intake (g/kg) was approximated based on body weight and number of 
reinforcements delivered. For all single treatment experiments (i.e., varenicline alone or 
alcohol prime alone), total alcohol responses, water responses, alcohol intake (g/kg) and 
total locomotion were analyzed with one-way repeated measures ANOVA. For experiments 
in which two treatment types were used (i.e., alcohol prime and varenicline), two-way 
repeated measures factorial ANOVA (with prime condition and varenicline dose as factors) 
was used. To assess changes in response patterns over time, multi-factor ANOVA was used 
with prime condition, varenicline condition and time point as factors. Post-hoc analysis 
(Tukey) was used to determine differences between specific treatment conditions. Statistical 
significance was determined at p≤0.05.
Results
Experiment 1: Effects of varenicline on the discriminative stimulus effects of alcohol
Varenicline administered alone had no alcohol-like discriminative stimulus effects, as 
alcohol-appropriate responses were below the substitution threshold (80%) and did not 
significantly differ from saline (Figure 2A). A significant effect on response rate was 
observed (F[3,15]=3.60, p=0.04; Figure 2B), however, posthoc analyses did not detect any 
significant differences. In contrast, varenicline pretreatment altered sensitivity to the 
discriminative stimulus effects of the alcohol training dose (1 g/kg). Repeated measures 
(RM) ANOVA showed a significant varenicline-induced decrease in alcohol-appropriate 
responses (F[3,15] = 9.682, p < 0.01, Figure 2C), with decreased alcohol-appropriate 
responses following 1.0 and 3.0 mg/kg varenicline doses as compared to saline (p < 0.05). 
Additionally, RM ANOVA showed a significant varenicline-induced reduction in response 
rate (F[3,15] = 7.677, p < 0.01, Figure 2D), at the highest varenicline dose (3.0 mg/kg) as 
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compared to saline (p < 0.05), indicating the likely disruption of motor behavior. Together, 
these results show that varenicline does not substitute for the discriminative stimulus effects 
of alcohol, and when administered prior to alcohol disrupts sensitivity to/alters the 
discriminative stimulus effects of a moderate alcohol dose (1 g/kg).
Experiment 2: Effects of varenicline on maintenance of alcohol self-administration
RM ANOVA showed a significant effect of varenicline pretreatment on total alcohol lever 
responses (F[3,33]= 32.788, p < 0.001, Figure 3A), alcohol intake (g/kg; F[3,33] = 22.929, p 
< 0.001, Table 2) and total locomotion (F[3,33] = 11.775, p < 0.001, Table 3). Post hoc 
analyses for each measure showed a significant reduction at the highest varenicline dose (3 
mg/kg) relative to vehicle (p < 0.05). Analysis of alcohol responding across the session 
showed a main effect of time (F[5,55] = 33.409, p < 0.01, Figure 3B) and a varenicline dose 
by time interaction (F[15,165] = 7.951, p < 0.01). Post-hoc analysis (Tukey) showed that 
rats treated with 3.0 mg/kg varenicline responded significantly less on the alcohol lever in 
the first 10 minutes of the session compared to saline (p < 0.05). Varenicline did not produce 
any effects on water lever responses (Table 1). In the independent locomotion assessment, 
varenicline (3 mg/kg) significantly decreased locomotion (i.e., total distance traveled) 
compared to saline (mean±S.E.M. beam breaks – saline: 2624.65±152.44; varenicline: 
1462.90±179.66; t[11] = 5.821, p < 0.001).
Experiment 3: Effects of alcohol priming on maintenance of alcohol self-administration
RM ANOVA demonstrated that alcohol priming significantly decreased total alcohol lever 
responses (F[2,18] = 3.703, p < 0.05, Figure 4A) and alcohol intake (g/kg) (F[2,18] = 6.407, 
p < 0.01, Table 2), with a significant reduction in both measures following the highest 
alcohol priming dose (1 g/kg) compared to water pretreatment (p < 0.05). Analysis of 
alcohol responses across the session showed a significant main effect of time (F[5,40] = 
4.454, p < 0.01, Figure 4B), but no alcohol dose by time interaction. Total water lever 
responses (Table 1) and total locomotion (Table 3) were not affected by alcohol priming. 
Interestingly, alcohol intake (g/kg) following the water prime was lower than baseline 
(Table 2), indicating that self-administration behavior was likely affected by the oral fluid 
administration. Indeed, previous studies have demonstrated that alcohol intake following 
oral administration of 2 ml of a subthreshold dose of alcohol decreases subsequent alcohol 
intake compared to a zero volume control (Czachowski et al. 2006).
Experiment 4: Effects of varenicline on maintenance of alcohol self-administration 
following priming
A two-way RM ANOVA showed a significant main effect of alcohol prime on alcohol 
responses (F[1,8] = 17.898, p < 0.01; Figure 5A), and alcohol intake (F[1,8] = 13.620, p < 
0.01; Table 2), with a significant reduction in both measures following alcohol (1 g/kg) 
priming injection relative to water injection (p<0.05). A significant main effect of 
varenicline treatment on alcohol responses (F[1,8] = 8.713, p < 0.05) and alcohol intake 
(F[1,8] = 12.816, p < 0.01; Table 2) was also observed, with significantly greater alcohol 
responding following varenicline (1 mg/kg) pretreatment relative to saline (p<0.05; Figure 
5A) and an alcohol priming-induced reduction in alcohol lever responses following vehicle 
pretreatment (p<0.05; Figure 5A). Interestingly, the alcohol-priming effect was not observed 
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following varenicline pretreatment, suggesting that varenicline blocked or counteracted the 
effects of priming. Similar to the data pattern observed in Experiment 3, alcohol intake 
(g/kg) following the water prime was lower than baseline (Table 2). There were no effects 
on total water lever responses (Table 1) or total locomotion (Table 3).
Examination of the pattern of alcohol responses across the session by RM factorial ANOVA 
showed a significant decrease in alcohol responding across the session (F[5,40] = 17.270, p 
< 0.01, Figure 5B). There was no priming by varenicline treatment interaction on alcohol 
lever responses. Additionally, alcohol lever responses across time showed a greater decrease 
following alcohol priming (1 g/kg) compared to water injection (F[1,32] = 6.042, p < 0.05). 
Conversely, alcohol lever responses were higher across the session following varenicline 
treatment (1 mg/kg) compared to saline treatment (F[1,32] = 11.392, p < 0.01). There was 
also a time period by varenicline interaction (F[5,40] = 3.355, p < 0.05), with significantly 
greater responding in minutes 5–10 following varenicline treatment (1 mg/kg) vs. saline (p < 
0.05).
Experiment 5: Effects of alcohol priming on alcohol-seeking behavior
Baseline alcohol intake (session prior to testing) was 0.80±0.1 g/kg. Alcohol priming 
significantly reduced alcohol-seeking behavior as indicated by a RM ANOVA (F[2,22] = 
9.785, p < 0.001, Figure 6A), with less alcohol lever responses compared to water (p < 
0.05). Analysis of alcohol responses across the session showed a significant main effect of 
time (F[5,55] = 21.966, p < 0.01, Figure 6B) and an alcohol dose by time interaction 
(F[10,110] = 3.257, p < 0.01). Post-hoc analysis showed that rats primed with alcohol (0.3 
and 1.0 g/kg) responded less in the first 5 minutes compared to water pretreatment. Priming 
had no effects on total water lever responses (Table 1) or total locomotion (Table 3).
Experiment 6: Effects of varenicline on alcohol-seeking behavior following priming
Baseline alcohol intake (session prior to testing) was 0.76±0.1 g/kg. Two-way RM ANOVA 
showed a main effect of alcohol priming on total alcohol lever responses (F[1,8] = 20.537, p 
< 0.05, Figure 7A), with a significant reduction observed following alcohol (1 g/kg) 
compared to water (p<0.05). Furthermore, there was a significant main effect of varenicline 
treatment on total alcohol lever responses (F[1,8] = 5.999, p < 0.05), with a significant 
increase following varenicline (1 mg/kg) compared to saline treatment (p<0.05). There was 
no priming by varenicline treatment interaction on alcohol lever responses. Post-hoc 
analysis confirmed an alcohol priming-induced reduction in alcohol lever responses 
following both vehicle and varenicline pretreatment (p<0.05). Analysis of response patterns 
across the probe-extinction session showed a reduction in alcohol lever responses over time 
(F[5,40] = 8.356, p < 0.01, Figure 7B). Furthermore, following alcohol priming, there was a 
greater reduction in lever pressing compared to water priming (F[1,32] = 12.617, p < 0.05). 
Conversely, lever pressing remained higher over time following varenicline treatment 
compared to saline (F[1,32] = 5.109, p < 0.05). There were no interactions between 
treatments or between treatments and time period. Total water lever responses (Table 1) and 
total locomotion (Table 3) was not affected by any treatment condition.
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The current experiments demonstrate several important findings. First, in the dose range 
tested, varenicline does not have alcohol-like effects similar to a moderate dose of alcohol (1 
g/kg). However, varenicline is capable of disrupting the discriminative stimulus effects of 
alcohol (1 g/kg) at a dose that did not alter response rate (1 mg/kg; Figures 2C and D). Next, 
varenicline pretreatment decreased alcohol self-administration (Figure 3), but only at a high 
dose (3 mg/kg) that also reduced locomotion during the self-administration session (Table 
3), in an independent assay, and as reflected by reduced response rate in the discrimination 
study (Figure 2D). Therefore, self-administration was not selectively reduced by varenicline 
pretreatment. Consistent with this finding, is other work in which a dose of 1.8 mg/kg 
varenicline or greater non-selectively decreased alcohol self-administration behavior 
(Ginsburg and Lamb 2013). The lack of a selective effect of varenicline on alcohol self-
administration is in contrast to other operant alcohol self-administration studies that show a 
varenicline-induced decrease in self-administration (Steensland et al. 2007; Wouda et al. 
2011). Several factors may contribute to these differential effects, including alcohol self-
administration history (daily g/kg, duration of training), response requirements, and strain. 
Indeed, recently, varenicline has been shown to have differential effects on alcohol and food 
related-behaviors depending on the operant testing conditions (Ginsburg and Lamb 2014). 
Additionally, varenicline has also been shown to reduce voluntary alcohol drinking under 
home cage drinking conditions (Feduccia et al. 2014; Steensland et al. 2007); however, 
given the lack of a specific work requirement (i.e., lever press, nose poke) under those 
conditions, direct comparison to the present work is difficult. Lastly, we found that 
varenicline prevented an alcohol-primed decrease in self-administration (Figure 5), resulting 
in potentiated alcohol self-administration relative to vehicle pretreatment. In contrast, under 
“probe-extinction” conditions, the alcohol-primed decrease in alcohol-seeking behavior was 
unaffected by varenicline (Figure 7).
An important aspect of the current studies was to assess the role of alcohol priming under 
self-administration and alcohol seeking (“probe-extinction”) conditions. Alcohol priming (1 
g/kg) reliably decreased alcohol self-administration (Experiment 3 and 4). These findings 
are in line with several previous studies that suggest that this effect is evidence for rats 
titrating intake based on the priming dose (Czachowski et al. 2003; Czachowski et al. 2006; 
Samson and Czachowski 2003). However, it is important to note, that even though self-
administration is reduced following priming (1 mg/kg), the amount of total alcohol exposure 
following the self-administration session (which includes the priming dose), is greater than 
the water-primed rats (~1.3 g/kg vs. 0.6 g/kg, respectively). Interestingly, priming was more 
effective at decreasing behavior under alcohol seeking conditions (Experiment 5), as both 
alcohol doses tested (0.3 and 1 g/kg) similarly decreased seeking behavior (Figure 6). This 
suggests that alcohol seeking behavior is more sensitive than self-administration behavior to 
alcohol priming. Consistent with this finding, is work by Jackson et al. (2003) in which 
alcohol priming (0.5 g/kg) significantly decreased alcohol-seeking behavior during probe-
extinction tests similar to the strategy incorporated in the present work. However, together, 
these findings are in contrast to those from reinstatement studies in which alcohol-seeking 
behavior is potentiated following alcohol priming at doses similar to those employed in the 
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present work (Le et al. 1999; Le et al. 1998; Samson and Chappell 2002). These different 
data patterns suggest that following extended periods of explicitly trained extinction and/or 
the consequent absence from alcohol (as employed in reinstatement studies), the functional 
impact of an alcohol priming cue to modulate behavior is increased compared to probe 
extinction trials as used in this work and by Jackson et al. (2003).
Interestingly, the consequences of varenicline pretreatment on alcohol priming varied under 
the different testing conditions. That is, under self-administration conditions (e.g., alcohol is 
available) varenicline blocked the effects of alcohol priming on self-administration, which 
resulted in potentiated self-administration relative to the vehicle control (i.e., self-
administration at levels similar to the water-primed controls; Figure 5). In contrast, under 
seeking conditions (i.e., “probe-extinction”) varenicline pretreatment did not alter alcohol-
primed seeking behavior (Figure 7). A plausible explanation for the potentiation of self-
administration behavior is that varenicline decreased sensitivity to the interoceptive effects 
of the alcohol priming dose, such that the priming cue no longer effectively regulated 
behavior. Indeed, this potential explanation is supported by the findings of Experiment 1. 
This disruption in sensitivity to alcohol may be related to varenicline having interoceptive 
effects of its own that compete with alcohol. Indeed, varenicline has been shown to have 
methamphetamine-like discriminative stimulus effects (Desai and Bergman 2014). 
Furthermore, Ginsburg and Lamb (2013) demonstrate that varenicline (1 mg/kg) increases 
alcohol self-administration, potentially through stimulant-like effects. However, this 
explanation cannot account for the lack of effect of varenicline pretreatment under seeking 
conditions.
In order to better understand the differences between the effects of varenicline on self-
administration and seeking conditions, response patterns across the session were examined. 
Under self-administration conditions (Experiment 4), a significant varenicline-induced 
increase in alcohol responses occurred early in the session (Figure 5B), consistent with 
previous work (Ginsburg and Lamb 2013). In contrast, under seeking conditions 
(Experiment 6) no varenicline-induced increase in responding was observed at any point 
during the session, although a trend was observed early in the session (Figure 7B). These 
differences in response patterns may, in part, be explained by different testing conditions. 
The combination of varenicline, alcohol priming, and the availability of alcohol in 
Experiment 4 may have led to the appropriate conditions under which motivation for 
alcohol-reinforced lever pressing was enhanced. In contrast, alcohol was not available in 
Experiment 6 (i.e., extinction session), potentially contributing to the decrease in responding 
observed. These findings demonstrate the importance of testing conditions in evaluating the 
effects of priming and the role of varenicline.
In the present work, the effects of a single varenicline dose to modulate a single alcohol 
priming dose were assessed. The varenicline dose was selected based on the results of the 
initial self-administration experiment (Experiment 2), in that it was necessary to select a 
dose that did not negatively impact motor behavior. The alcohol priming dose was selected 
based on the finding that pretreatment with a moderate alcohol dose (1 g/kg) effectively 
reduced subsequent self-administration and alcohol-seeking behavior (Experiments 3 and 5, 
respectively). However, it will be informative for future work to examine a dose range of 
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both compounds. Additionally, the current experiments were undertaken in a non-
dependence model of alcohol intake. Varenicline has been shown to be effective at reducing 
alcohol consumption in individuals that have been heavy drinkers for many years (for 
review see (Erwin and Slaton 2014)); therefore, it will be interesting to examine the effects 
of varenicline on operant self-administration under conditions of dependence. Moreover, the 
behavioral profile of varenicline in the present study (i.e., lack of selective effect of 
varenicline on operant alcohol self-administration, disruption of sensitivity to the 
discriminative stimulus effects of alcohol, and reduced ability of alcohol priming to 
appropriately regulate self-administration behavior), suggests that varenicline may actually 
present a risk factor for non-dependent drinkers (e.g., social drinkers) using varenicline as a 
smoking cessation aid. Interestingly, one of the label indications for varenicline is the 
recommendation that individuals prescribed varenicline to quit smoking reduce their alcohol 
consumption while taking the drug. As such, further mechanistic and behavioral studies are 
needed to characterize the therapeutic value of varenicline in the treatment of alcohol use 
disorders, and also the potential impact on drinking patterns in social drinkers, especially 
those using varenicline as a smoking cessation aid.
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The experimental design and timeline for the experiments showing training history for the 
self-administration (SA) experiments and within group testing. The three separate timelines 
represent different group of rats.
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Discriminative stimulus effect of alcohol in combination with varenicline and varenicline 
alone. Mean (±SEM) alcohol appropriate-responses (A) and response rate (B) following 
varenicline injection in alcohol discrimination-trained rats. Varenicline did not have alcohol-
like discriminative stimulus effects. Mean (±SEM) alcohol-appropriate responses (C) and 
response rate (D) following varenicline pretreatment prior to the alcohol training dose (1 g/
kg). Horizontal dashed line (>80%) represents full expression of the discriminative stimulus 
effects of alcohol. *- p < 0.05, different from saline treatment.
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Effects of varenicline on alcohol self-administration. Mean (±SEM) alcohol responses (A) 
and alcohol responses across the session (B) following varenicline injection. * - p < 0.05 
different from saline treatment.
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Effects of alcohol priming on alcohol self-administration. Mean (±SEM) alcohol responses 
(A) and alcohol responses across the session (B) following alcohol priming doses. * - p < 
0.05 different from water treatment.
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Effects of alcohol priming combined with varenicline treatment on alcohol self-
administration. Mean (±SEM) alcohol responses (A) and alcohol responses across the 
session (B) following varenicline injection and alcohol priming in rats trained to self-
administer alcohol. * - p < 0.05, different from water (A) or saline (B).
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Effects of alcohol priming on alcohol seeking behavior. Mean (±SEM) alcohol responses 
(A) and alcohol responses across the session (B) following alcohol priming and under probe-
extinction conditions. * - p < 0.05, different from water pretreatment.
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Effects of alcohol priming combined with varenicline on alcohol seeking behavior. Mean 
(±SEM) alcohol responses (A) and alcohol responses across the session (B) following 
alcohol priming and varenicline pretreatment, under probe-extinction conditions. * - p < 
0.05, different from water pretreatment.
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Table 1
Total (mean±S.E.M.) water responses for the alcohol self-administration experiments.
Experiment 2 Varenicline dose (mg/kg, IP)
0 0.3 1 3
2.4±0.6 2.0±0.8 1.9±0.8 2.2±0.7
Experiment 3 Alcohol prime dose (g/kg, IG)
0 0.3 1
2.2±0.7 1.9±0.6 2.6±0.6
Experiment 4 Varenicline dose (mg/kg)/Alcohol prime dose (g/kg, IG)
0/0 0/1 1/0 1/1
2.1±0.7 2.4±1.0 1.5±0.6 1.9±0.5
Experiment 5 Alcohol prime dose (g/kg, IG)
0 0.3 1
2.3±0.8 2.6±0.6 1.9±0.7
Experiment 6 Varenicline dose (mg/kg)/Alcohol prime dose (g/kg, IG)
0/0 0/1 1/0 1/1
2.3±0.8 1.6±0.6 2.2±1.1 2.1±1.6
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Table 3
Locomotion (total beam breaks; mean±S.E.M.) for the self-administration experiments.
Experiment 2 Varenicline dose (mg/kg, IP)
0 0.3 1 3
774±36.5 862.7±60.6 724.4±48.4 492.3±88.1*
Experiment 3 Alcohol prime dose (g/kg, IG)
0 0.3 1
685.2±83.6 729.4±72.6 755.5±68.7
Experiment 4 Varenicline dose (mg/kg)/Alcohol prime dose (g/kg, IG)
0/0 0/1 1/0 1/1
748.7±77.9 764.8±54.8 829.2±65.1 760.6±45.1
Experiment 5 Alcohol prime dose (g/kg, IG)
0 0.3 1
751.6±68.6 788.2±49.5 766.4±64.3
Experiment 6 Varenicline dose (mg/kg)/Alcohol prime dose (g/kg, IG)
0/0 0/1 1/0 1/1
848.4±39.9 954.2±96.2 860.7±52.3 916.5±68.2
*
denotes significant difference from 0 (p<0.05)
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